Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

SARS Covid virus

The ‘G2P-UK’ National Virology Consortium* will study how mutations in the virus affect key outcomes such as:

  • how transmissible it is
  • the severity of COVID-19 it causes
  • the effectiveness of vaccines and treatments.

The Fodor Lab (Sir William Dunn School of Pathology) and the Grimes Lab (Nuffield Department of Medicine) are pleased to be part of this project through their collaboration on the SARS-CoV-2 RNA polymerase. Specifically, they will be addressing how emerging mutations in the SARS-CoV-2 replicase genes affect the ability of the virus to replicate its RNA genome and, in collaboration with the other partners in the consortium, how these changes impact the properties of the virus, such as transmissibility, severity of the disease it causes and the immune responses it triggers.

The full story is available on the UKRI website

Similar stories

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the NDM's Jenner Institute and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

The Ling Felce Award to promote cross-disciplinary excellence in bioinformatics

Following on from the tragic death of Dr Ling Felce at the Plain roundabout in March 2022, the CAMS-Oxford Institute within the Nuffield Department of Medicine are seeking funds to start an award in her memory.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

Pandemic Sciences Institute formally launched in Oxford

The University of Oxford’s Pandemic Sciences Institute (PSI) has been formally launched at a two-day event at the Blavatnik School of Government, at which the lead researchers set out its direction and strategy for the next five years.

CAMS Oxford Institute unveiled at virtual ceremony

Oxford University and the Chinese Academy of Medical Sciences (CAMS) signed a cooperation agreement at a virtual unveiling ceremony of the CAMS Oxford Institute.

Turing Fellowship for NDM researcher

Thirty-three University of Oxford researchers have been named Turing Fellows for the 2021/22 academic year, including Dr Benjamin Schuster-Böckler from the Ludwig Institute for Cancer Research.